The FDA has accepted for review the NDA for vepdegestrant to treat ESR1-mutated, ER+, HER2- advanced breast cancer.

Physician attire impacts patients' perceptions of professionalism, trust, and communication, but perceptions are highly context-dependent, research suggests.